vs
Immunovant, Inc.（IMVT）与香港置地（LAND）财务数据对比。点击上方公司名可切换其他公司
香港置地的季度营收约是Immunovant, Inc.的2.0倍（$16.6M vs $8.4M），Immunovant, Inc.同比增速更快（140.7% vs -1.5%）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
香港置地是一家专注于房地产投资、管理及开发的集团，在亚洲各地布局商业与住宅地产业务。目前集团在亚洲持有并运营约85万平方米的写字楼及商业零售物业，核心布局中国香港与新加坡两地，其中香港中环的商业物业规模居当地首位，新加坡则主要通过合资持有约16.5万平方米的写字楼空间。
IMVT vs LAND — 直观对比
营收规模更大
LAND
是对方的2.0倍
$8.4M
营收增速更快
IMVT
高出142.2%
-1.5%
损益表 — Q4 FY2024 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $16.6M |
| 净利润 | $-75.3M | — |
| 毛利率 | — | — |
| 营业利润率 | -896.2% | 200.3% |
| 净利率 | -899.0% | — |
| 营收同比 | 140.7% | -1.5% |
| 净利润同比 | -26.7% | — |
| 每股收益（稀释后） | $-0.50 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTLAND
| Q1 26 | — | $16.6M | ||
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $17.8M | ||
| Q2 25 | — | $12.3M | ||
| Q1 25 | — | $16.8M | ||
| Q4 24 | — | $21.1M | ||
| Q3 24 | — | $22.6M | ||
| Q2 24 | — | $21.3M |
净利润IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | — | $-7.9M | ||
| Q1 25 | — | $15.1M | ||
| Q4 24 | — | $540.0K | ||
| Q3 24 | — | $6.0K | ||
| Q2 24 | — | $-823.0K |
营业利润率IMVTLAND
| Q1 26 | — | 200.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
净利率IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | 10.2% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | -64.1% | ||
| Q1 25 | — | 89.9% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | -3.9% |
每股收益（稀释后）IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | $-0.16 | ||
| Q2 24 | — | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $617.8M | $688.3M |
| 总资产 | $666.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | $27.2M | ||
| Q3 25 | — | $11.3M | ||
| Q2 25 | — | $30.5M | ||
| Q1 25 | — | $42.9M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $13.2M | ||
| Q2 24 | — | $49.8M |
总债务IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | $473.6M | ||
| Q3 25 | — | $480.4M | ||
| Q2 25 | — | $496.4M | ||
| Q1 25 | — | $498.8M | ||
| Q4 24 | — | $527.5M | ||
| Q3 24 | — | $530.7M | ||
| Q2 24 | — | $549.4M |
股东权益IMVTLAND
| Q1 26 | — | $688.3M | ||
| Q4 25 | — | $670.3M | ||
| Q3 25 | — | $661.8M | ||
| Q2 25 | — | $670.1M | ||
| Q1 25 | — | $689.9M | ||
| Q4 24 | — | $687.2M | ||
| Q3 24 | — | $691.2M | ||
| Q2 24 | — | $708.5M |
总资产IMVTLAND
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.4B |
负债/权益比IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 0.73× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.72× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | — |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | — |
| 自由现金流率自由现金流/营收 | -714.4% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-214.6M | — |
8季度趋势，按日历期对齐
经营现金流IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | — | $3.9M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $29.5M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $15.9M |
现金转化率IMVTLAND
| Q1 26 | — | — | ||
| Q4 25 | — | 1.66× | ||
| Q3 25 | — | -5.77× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 54.72× | ||
| Q3 24 | — | -227.83× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
